<DOC>
	<DOCNO>NCT00989092</DOCNO>
	<brief_summary>This phase 2 , multicenter , randomize , open-label , comparative study design determine effect darbepoetin alfa hospital day , economic outcome , health relate quality life ( HRQOL ) anemic patient nonmyeloid malignancy receive chemotherapy . Participants randomly assign 4:1 allocation ratio receive either 21 week darbepoetin alfa treatment ( treatment group ) 12 week observation follow 9 week darbepoetin alfa treatment ( observation group ) .</brief_summary>
	<brief_title>Darbepoetin Alfa Anemia Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>nonmyeloid malignancy ( include lymphocytic leukemia ) anemia ( hemoglobin concentration less equal 11.0 g/dL ) due cancer and/or previous chemotherapy radiotherapy Eastern Cooperative Oncology Group performance status 0 2 adequate liver renal function 18 year old history recombinant human erythropoietin therapy , cytotoxic chemotherapy , 30 Gy radiotherapy whole pelvis within 4 week screen acute myelogenous leukemia , chronic myelogenous leukemia , myelodysplastic syndrome know hematologic disorder could cause anemia inflammatory cardiac disorder previous positive antibody response erythropoietic agent history pure red cell aplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>anemia cancer</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Aranesp</keyword>
</DOC>